213 related articles for article (PubMed ID: 32089823)
1. Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication.
Losasso M; Bostrom B; Messinger Y
F1000Res; 2019; 8():1007. PubMed ID: 32089823
[No Abstract] [Full Text] [Related]
2. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
3. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.
Cooper SL; Young DJ; Bowen CJ; Arwood NM; Poggi SG; Brown PA
Pediatr Blood Cancer; 2019 Aug; 66(8):e27797. PubMed ID: 31099154
[TBL] [Abstract][Full Text] [Related]
4. Allergic reactions associated with pegaspargase in adults.
Chang A; Kim M; Seyer M; Patel S
Leuk Lymphoma; 2016 Jul; 57(7):1665-8. PubMed ID: 26461960
[TBL] [Abstract][Full Text] [Related]
5. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
6. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
[TBL] [Abstract][Full Text] [Related]
7. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of asparaginase activity levels following treatment with pegaspargase.
Bleyer A; Asselin BL; Koontz SE; Hunger SP
Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a Standardized Premedication and Therapeutic Drug Monitoring Protocol for Pegaspargase to Prevent Hypersensitivity Reactions.
Babcock KJ; Kinnunen A; Egelund T; Ng JS; Joyce MJ
J Pediatr Pharmacol Ther; 2022; 27(3):232-236. PubMed ID: 35350153
[TBL] [Abstract][Full Text] [Related]
11. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
Pediatr Hematol Oncol; 2014 May; 31(4):311-7. PubMed ID: 24498943
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Vrooman LM; Blonquist TM; Stevenson KE; Supko JG; Hunt SK; Cronholm SM; Koch V; Kay-Green S; Athale UH; Clavell LA; Cole PD; Harris MH; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Place AE; Schorin MA; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2021 Nov; 39(31):3496-3505. PubMed ID: 34228505
[TBL] [Abstract][Full Text] [Related]
13. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
14. Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with acute lymphoblastic leukemia.
McCormick M; Lapinski J; Friehling E; Smith K
Pediatr Blood Cancer; 2021 Aug; 68(8):e29051. PubMed ID: 33860989
[TBL] [Abstract][Full Text] [Related]
15. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
16. Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.
Abbott LS; Zakova M; Shaikh F; Shewaramani N; Punnett A; Dupuis LL
Paediatr Drugs; 2015 Aug; 17(4):315-21. PubMed ID: 25862348
[TBL] [Abstract][Full Text] [Related]
17. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
[TBL] [Abstract][Full Text] [Related]
18. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
19. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.
Hoshitsuki K; Zhou Y; Miller AM; Choi JK; Swanson HD; Bhakta NH; Jeha S; Karol SE; Ribeiro RC; Rubnitz JE; Mullighan CG; Cheng C; Yang JJ; Relling MV; Pui CH; Inaba H
Leukemia; 2023 Sep; 37(9):1782-1791. PubMed ID: 37543655
[TBL] [Abstract][Full Text] [Related]
20. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]